enVVeno Medical Corp

# Signal Note: Perceptive Advisors Initiates NVNO Position Perceptive's entry into enVVeno suggests conviction in the company's venous insufficiency pipeline, likely centered on its investigational percutaneous treatment platform designed to address chronic venous disease—a large, underserved market with limited minimally invasive options. The relatively modest position size (~564K) indicates either early-stage conviction or portfolio diversification rather than a major conviction bet, warranting monitoring for upcoming clinical readouts or partnership announcements that could validate the technology.